Overview

Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis

Status:
Recruiting
Trial end date:
2023-03-13
Target enrollment:
Participant gender:
Summary
The purpose of this proof of concept study is to determine whether CMK389 displays the safety and efficacy profile to support further development in chronic pulmonary sarcoidosis.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals